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A synthetic bone substitute based on calcium hydroxyapatite (CHA) and poly(lactic-co-glycolic) acid (PLGA), described in this
paper, was synthesized to fulfill specific requirements like biodegradability, satisfying mechanical properties, optimal porosity and
nanotopology, osteoinductive and osteoconductive properties, and so forth. Structural and morphological properties of the new
scaffold were analyzed by micro computed tomography and scanning electron microscopy, while its physicochemical properties
were investigated by X-ray diffraction and infrared spectroscopy. In vivo biological investigations of the synthesized scaffold were
conducted over the cutaneous irritation and biofunctionality assays on rabbits and the test of acute systemic toxicity on mice.
The results showed that the scaffold is not irritant and that it does not exhibit any symptoms of acute toxicity. Biofunctionality
assays which include evaluation of the presence of various cells of immune response, the presence of neoangiogenesis, percentage
of mineralization of newly formed bone, and fibroplasia in the tissue indicated that the new scaffold is suitable for the application
in maxillofacial and dental surgery as a bone substitute. Also, it showed significant advantages over commercial product Geistlich
Bio-Oss from the aspect of some parameters of immunological response.
1. Introduction
Bone tissue engineering techniques have become the main
strategy for permanent repair of bone defects, since the
use of auto- and allografts is accompanied with the source
limitation and immunologic rejection due to their natural
origin [1–3]. As many investigations showed, biodegradable
porous 3D structures, known as scaffolds, are the most
promising solution, because they act as a temporary physical
support until their total degradation and replacement by
new bone, and, on the other hand, their porosity enables
cell growth and facilitates tissue regeneration and vascular-
ization [4–6]. These scaffolds should also be biocompatible,
osteoinductive, and osteoconductive, possessing mechanical
propertiesmatching those of the tissue they are replacing, and
geometrically and functionally designed to mimic the native
ECM environment [7–10]. This can be achieved by specific
composite scaffold construction, with ceramic part which
mimics bone structural hierarchy and thin polymer layer
which improves mechanical properties and cell attachment
and proliferation. Bearing all that in mind, a composite
scaffold of CHA and PLGA, named as ALBO-OS, with
very high porosity, was developed as an innovative product.
CHA was chosen as one of the most widely used ceramic
materials in bone tissue engineering, since it represents the
component of natural bone [11]. PLGA, present as a thin
coating on the CHA scaffold, is commonly used in tissue
engineering due to satisfying mechanical properties, high
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purity, convenient processing, and adjustable degradation
rate to match the healing rate of damaged tissue [12, 13]. The
role of the PLGA coating, beside improvement of mechanical
properties, is to enhance the scaffold surface for various cell
activities, like adhesion, density of their occupation, release of
cytoplasmic metabolites, and so forth [14]. Biocompatibility
and biofunctionality of so-designed scaffold were evaluated
in vivo by the test of acute systemic toxicity performed on
mice and the test of cutaneous irritation and biofunctionality
assays performed on rabbits. All performed in vivo tests,
and particularly themost important assay of biofunctionality,
revealed extraordinary results which underline their real
potential for clinical application.
2. Materials and Methods
2.1. Scaffold Preparation and Characterization. ALBO-OS
scaffold was manufactured using the method of polymer
foam template.Water suspension of hydrothermally obtained
CHA powder, whose synthesis is described in our previous
references [15, 16], was poured over the polymer foam, with
corresponding pore size distribution. The foam was burnt
out after which porous scaffold structure was obtained. The
system was finally sintered at 1200∘C. The obtained porous
CHA compact was further disintegrated into granules of
suitable size and PLGA thin film was deposited over them
to obtain final product—ALBO-OS scaffold. Details of the
scaffold synthesis are given in Appendix A.
Phase analysis of porous CHA was performed by X-ray
diffraction (XRD) using a Philips PW 1050 diffractometer
with Cu-K𝛼1-2 lamp, whereby the data were collected in the
2𝜃 range from 15 to 65∘, in steps of 5∘ and exposure time
of 2 seconds per step. Phase analysis of ALBO-OS scaffold
was performed by Fourier transform infrared spectroscopy
(FTIR) using a Nicolet 380 FTIR Spectrometer (Thermo
Electron Corporation); infrared spectra were recorded in the
spectral range of 4000–400 cm−1.
Microstructure of the scaffold was analyzed by scanning
electronmicroscopy (SEM, JEOL JSM-5300microscope) and
micro computed tomography (CT) (SkyScan, Bruker 1172,
Kontich, Belgium). Details of the CT analysis are given in
Appendix B.
Nanoporosity of the scaffold was estimated by high-
pressure mercury intrusion porosimeter (Carlo Erba
Porosimeter 2000 with Milestone 100 Software System). The
porosimeter operates in the pressure interval 0.1–200MPa,
enabling estimation of pores in interval 7.5–15,000 nm.
2.2. Test of Primary Cutaneous Irritation after ALBO-OS
Application. This study was performed according to modern
requirements for animal care: ISO 10993-2:2006 (E) Animal
Welfare Requirements.
For the test of primary cutaneous irritation, New Zealand
white rabbits were used according to ISO 10993-10:2010 (E)
standard.Three animalswere used, twomales and one female.
Their age was 3 months and their body weight was 2.5 ±
0.5 kg. The animals were quarantined three weeks before the
start of the experiment. Health status of the animals was
checked and only clinically healthy rabbits were taken for the
investigations, which have not been previously used in other
experiments and with no cutaneous lesions. Twenty-four
hours before application of ALBO-OS, rabbits were carefully
shaved in the dorsal area, on two lateral sites with the surface
of 14 × 14 cm.
ALBO-OS was applied directly to the shaved skin of each
of three rabbits in both lateral cranial fields, making a total of
six experimental sites. The size of each test preparation was
2.5 × 2.5 cm and was covered with Sensifix patch (5 × 5 cm).
As a control, 6 areas of the same size (2.5 × 2.5 cm) were
used, which are located caudal to the experimental sites on
the bodies of the same animals. Control surfaceswere covered
only with Sensifix patches (5 × 5 cm). The sample was left in
contact with the skin for a period of 4 hours after which it was
removed.
The observation of cutaneous lesionswas performed 1, 24,
48, and 72 hours after removal of the preparation. Cutaneous
changes on the skin were evaluated for any specified period
and marked according to a numerical scale (Table 1).
Irritation score (IS) was obtained by dividing the total
sum of the numerical values for erythema and edema for
all experimental animals by their number (three). Numer-
ical values obtained for edema and erythema 1 hour after
removal of the preparation were neglected. Index of primary
cutaneous irritation (PII) was calculated by dividing the IS
value by the number of application sites (six). Based on the PII
value, the preparation was classified according to the values
given in Table 2.
2.3. Test of Acute Systemic Toxicity in Mice after ALBO-OS
Application. This study was performed according to modern
requirements for animal care: ISO 10993-11:2006 (E), Part 11:
Biological Evaluation of Medical Devices.
For the test of acute systemic toxicity, mice (NMRI HAN)
were used according to ISO 10993-2:2006 (E) standard. Ten
animals were used, six male and four female. Their age was 8
weeks at the beginning of the experiment and 10 weeks at the
end of the experiment.Their body weight at the beginning of
the experiment was 18–22 g. The animals were placed in the
Makrolon cages with a cover of steel wires in groups of three
males and two females. The temperature in the room was
between 18 and 25∘C, and a relative humidity was between
30 and 70%. The animals had free access to food and water.
The health status of the animals during the experiment was
monitored daily.
Test preparations were prepared according to the stan-
dard ISO 10993-12:2007(E): Sample Preparation and Reference
Materials. The mass of 2 g of ALBO-OS was immersed in
10mL of sterilized tap water and thermostated at 37∘C. After
72 hours, the obtained extract was decanted.
The extract was applied once directly into stomach of
experimental animals, using gastric probe, in a volume of
1mL. Five mice (3 male and 2 female) were treated with the
extract, while the other five served as a control group (they
were given 1mL of water in the same way). The animals
were observed 14 days after the application and signs of
toxic reactions were monitored twice a day. After 14 days, all
Journal of Nanomaterials 3
Table 1: Numerical scale for evaluation of the skin reaction.
Degree
Erythema
Without erythema 0
Mild erythema 1
Well defined erythema 2
Expressed erythema 3
Heavy erythema (deep lesions, scabs, burns, and necrosis) 4
Edema
Without edema 0
Very mild edema 1
Mild edema (well defined edges) 2
Moderate edema (∼1mm thickness) 3
Heavy edema (thickness > 1mm, spreading out of application site) 4
Total possible score of irritation 8
Table 2: Index of primary cutaneous irritation.
PII Classification of the test preparation
0–0.4 Nonirritant
0.5–1.9 Mild irritant
2–4.9 Irritant
5–8 Very irritant
animals were sacrificed and pathoanatomic examination was
made.
2.4. Biofunctionality Assays. This study was performed on
New Zealand white rabbits. Experiments were approved by
the Ethics Committee of the Faculty of Dentistry, Belgrade
University (number 36/12 from 23.11.2009) and were per-
formed according to ISO 10993-2 Animal Welfare Require-
ments (modern requirements for animal care). Twenty ani-
mals were used in the investigation, ten males and ten
females. They were 4 months old at the beginning and 7
months at the end of the experiment. The rabbits’ weight was
3.0±0.5 kg.Their health status was checked daily.The rabbits
were kept in standard cages, one animal per cage, placed in
a room with temperature of 22 ± 4∘C and relative humidity
of 55 ± 10%.They had ad libitum access to standard food for
rabbits.
Surgical procedure and implantation details are given in
Appendix C. After the assessment period of six, nine, and
twelve weeks, the animals were sacrificed and the parietal
bones were cut and samples were prepared for the analysis.
After assessment period of six and nine weeks, 6 samples with
implanted ALBO-OS and 4 samples with implanted Bio-Oss
were analyzed. After twelve weeks, a total of 44 samples were
analyzed: 20 samples with implanted ALBO-OS, 10 samples
left empty as negative controls, and 14 sampleswith implanted
Bio-Oss as positive controls.
2.4.1. Tissue Preparation and Histological Evaluation. Tissue
samples of the parietal bone, which corresponded to the
full thickness critical sized (6.0mm in diameter) defects,
were fixed in 10% formalin. After decalcification, all samples
were embedded in paraffin and serial tissue sections of 5𝜇m
thickness were cut (4 per sample). Slides were stained with
the Masson’s trichrome (MT) stains and observed by optical
microscopy (Olympus 5 microscope) using Olympus Cell-B
morphometric software. Histopathological parameters were
analyzed qualitatively, semiquantitatively, and quantitatively
(at magnifications: 40x, 100x, and high power magnification
(HPM) of 200x).
The immune response intensity was analyzed over the
presence of macrophages, giant cells, lymphocytes, plasma
cells, and basophiles, expressed as the number of cells
within one microscopic field under HPM (0 cells/HPM, 1–
5 cells/HPM, and 5–10 cells/HPM) and over the presence of
neoangiogenesis (0 blood vessels/HPM, 1–3 bv/HPM, and 4–
7 bv/HPM). The percentage of mineralization (0, <25%, 25–
50%, 50–75%, and 75–100%) of newly formed bone and the
presence of connective tissue (0–25%, 26–50%, and 51–100%)
were also examined.
2.4.2. Statistical Analysis. The results are presented as counts
(percentages). Chi-square test for trend was used to compare
various biofunctionality parameters of ALBO-OS and Bio-
Oss. All data analyses were performed with SPSS 20.0
(IBM corp.) statistical package. All 𝑝 values less than 0.05
were considered significant. Multiple comparisons were done
without Bonferroni correction. In all cases, exact tests were
used due to small sample sizes.
3. Results
3.1. Scaffold Characterization. The phase composition of the
CHA, as the main constituent of ALBO-OS, corresponds
to calcium hydroxyapatite Ca
10
(PO
4
)
6
(OH)
2
, as confirmed
by XRD analysis (Figure 1). Diffraction peaks characteristic
for CHA were present at 2𝜃 values of 25.95, 28.20, 28.95,
31.82, 32.19, 32.84, 34.07, 39.58, 46.54, 49.54, 53.28, and 64.02∘,
with corresponding planes (002), (102), (120), (121), (112),
(300), (202), (310), (222), (123), (004), and (304), respectively.
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Figure 1: XRD pattern of CHA.
Re
lat
iv
e i
nt
en
sit
y 
(a
.u
.)
100
80
60
40
20
0
4000 500
Wave number (cm−1)
100015002000250030003500
CHA PLGA
PLGA PLGA
PLGA
CHA
CHA
PLGA
Figure 2: FTIR spectrum of ALBO-OS.
The crystallite size was 15 nm, as calculated using Scherer’s
equation.
FTIR spectrumofALBO-OS (Figure 2) showed the bands
characteristic for its both components, CHA and PLGA. The
bands around 3570, 1640, 650, and 600 cm−1 correspond
to vibrations of OH− groups in CHA. The bands at 550
to 640 correspond to symmetric stretching of PO
4
3, while
the bands at about 430 to 450 cm−1 correspond partially to
the ]
2
symmetric mode of the PO
4
3− vibration. The bands
corresponding to CO
3
2− were found around 1458, 1420, and
870 cm−1, which confirmed that carbonate apatite of type B
was obtained, which is very important from the biological
standpoint, since type B is themost active form of carbonated
apatite prevailing in bones of young people, while the A type
is prevailing in bones of elderly people. The bands corre-
sponding to PLGA were found at the following: 2995 cm−1
which can be assigned to the C–H asymmetric stretching
vibration; around 2950 and 2880 cm−1 corresponding to the
C–Hsymmetric stretch; 1760 cm−1 corresponding to theC=O
Table 3: Pore size distribution.
Pore diameter, 𝜇m Volume partition in the total porevolume, %
2.23 6–90
2.76 90–150
3.26 150–210
6.13 210–294
11.13 294–390
21.06 390–498
19.1 498–594
18.38 594–690
15.95 690–774
stretch; about 1100–1280 cm−1 corresponding to the aliphatic
etherC–O–C stretch; 1400–1500 cm−1 corresponding toCH
2
,
CH
3
, and CH deformation vibrations; and around 750 cm−1
which can be attributed to the rocking motion of long CH
2
chain.
A very high porosity of the CHA scaffold, as the main
constituent of ALBO-OS, can be seen in micro CT image
(Figure 3(a)). CTAn 1.14.4.1 software enabled detailed analysis
of porosity parameters, showing that open and total porosity
are equal (75.4%), volume partition of closed pores is negli-
gible, and the number of connected pores per mm3 is very
high (13.6).The value of the structure model index parameter
(1.1) indicated cylindrical shape of the pores. CT also gave
the information about pore size and pore size distribution
(Table 3).
SEM analysis enabled deeper insight into the structure
of CHA granules (Figure 3(b)) showing a very developed
scaffold internal geometry with particles of cylindrical shape.
Particle length is in the range 300–900 nm and the width is
between 180 and 250 nm. Pores between the particles range
from 90 to 300 nm.
The nanostructure of the scaffold walls was additionally
investigated by mercury porosimetry which showed the
presence of nanopores in the diameter range 30–400 nm,with
prevailing pores in the range 100–200 nm.
3.2. Results of the Cutaneous Irritation Test. Results of the test
of cutaneous irritation after application of ALBO-OS on the
skin of New Zealand white rabbits are shown in Table 4. As it
can be seen, ALBO-OS showed no irritating effects, since all
values for erythema and edema were zero. The same values
were obtained for control sites.
3.3. Results of the Acute Systemic Toxicity Test. Treated ani-
mals did not exhibit signs of toxic reactions immediately
after application as well as later in the observations. They
behaved normally, in line with expectations for their species,
sex, age, and environment. The reaction of the animals to
the provoked behavior was normal and expected. There were
no signs of neurological dysfunction. Motor activity and
muscle tonus were regular as well as respiration and heart
rhythm. Hygienic behavior of animals was normal. The eyes
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Figure 3: (a) CT image and (b) SEMmicrograph of ALBO-OS.
Table 4: Evaluation of the irritation degree of ALBO-OS.
Rabbit
24 h 48 h 72 h
PIIErythema Edema Erythema Edema Erythema Edema
L D L D L D L D L D L D
1 0 0 0 0 0 0 0 0 0 0 0 0
0,002 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0 0 0 0
L: left application site on the rabbit’s back.
D: right application site on the rabbit’s back.
were clear and clean, and nasal openings and other natural
openings were clean. No changes on the skin were observed.
Experimental animals did not show eating disorders; they
ate and drank water in the usual way. Consumption of food
and water for the experimental and control animals was
not significantly different. There was no significant variation
in body weight gain of experimental compared to control
animals. During the experimental period, there was no
death of the experimental animals. Postmortemmacroscopic
examination of organs and tissues did not show changes in
any animal, from both the treated and the control group.
3.4. Results of the Biofunctionality Assays. Preliminary anal-
ysis of the tissue samples was performed 6 and 9 weeks
after implantation of ALBO-OS and Bio-Oss (Figures 4 and
5). Six defects filled with ALBO-OS and four defects filled
with Bio-Oss were analyzed. Although the cells of immune
response were counted for each sample, statistical analysis
was not performed due to insufficient number of samples.
However, the number of samples was enough to estimate
the degree of immune response of both materials. After
6 weeks, particles of both materials are visible (Figure 4).
Fibrovascular proliferation with many blood vessels and
woven bone production can be observed which indicates
that the process of new bone formation is in an initial
phase for both materials. The data obtained after 9 weeks
showed significantly milder immune response in defects
filled with ALBO-OS than in those with Bio-Oss since much
larger number of giant cells in the defects with Bio-Oss was
observed (Figure 5). Comparative morphometric analysis of
the defects showed larger fields of mineralization in ALBO-
OS (181 𝜇m) than in Bio-Oss (96 𝜇m) and proportionately
more pronounced fibrous proliferation in Bio-Oss (86 𝜇m)
than in ALBO-OS (180 𝜇m).
The tissue preparations obtained 12 weeks after implan-
tation of test materials (ALBO-OS, Bio-Oss, and empty
defects) were analyzed for the presence of cells of immune
response: macrophages, giant cells, lymphocytes, plasma
cells, and basophiles. A total of 44 samples were analyzed: 20
with ALBO-OS, 14 with Bio-Oss, and 10 without implanted
materials. Results were expressed as a percentage of defects
filled with ALBO-OS/Bio-Oss or empty defects in which the
cells of immune response were present in certain number
(Table 5).
Morphometric analysis revealed that in 70–75%of defects
filledwithALBO-OS there were no cells of immune response,
1–5 cells/HPM were present in 25–30% of defects, and
more than 5 cells/HPM were not observed in any defect.
As it can be seen in Table 1, in defects filled with Bio-
Oss, macrophages and giant cells were present in 80–85%
of defects, showing significantly stronger immune response
than ALBO-OS. The difference in presence of the other cells
(lymphocytes, plasma cells, and basophils) is less expressed.
This was confirmed by post hoc testing which indicated the
significant differences between Bio-Oss and ALBO-OS: 𝑝 =
0.002 in the case of macrophages and 𝑝 < 0.001 in the case of
giant cells (statistical differences between ALBO-OS/Bio-Oss
and empty defects are given and discussed in Appendix D).
Neoangiogenesis expressed over the number of blood
vessels showed similar behavior for ALBO-OS and Bio-Oss,
while the percentages ofmineralization and connective tissue
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Table 5: Immunological response 12 weeks after implantation of ALBO-OS and Bio-Oss.
Immune cells Number of cells per HPM Percentage of defects 𝑝 valueALBO-OS/Bio-OssALBO-OS Bio-Oss Empty defect
Macrophages
No 70 21.4 0
0.0021–5 30 50 20
5–10 0 28.6 80
Giant cells
No 70 14.3 10
<0.0011–5 30 57.1 20
5–10 0 28.6 70
Lymphocytes
No 75 64.3 40
0.2571–5 25 21.4 60
5–10 0 14.3 0
Plasma cells
No 75 71.4 40
0.7461–5 25 21.4 60
5–10 0 7.1 0
Basophils
No 75 71.4 50
0.5621–5 25 14.3 50
5–10 0 14.3 0
(a) (b)
Figure 4: Comparative review of defects 6 weeks after implantation, for (a) ALBO-OS and (b) Bio-Oss. Particles of material ALBO-OS
(encircled in yellow) and Bio-Oss (encircled in green) surrounded by tissue response on material’s presence. Note new forming fibrovascular
proliferation with many blood vessels and woven bone production (HE stain, magnification 100x).
(a) (b)
Figure 5: Comparative review of defects 9 weeks after implantation for (a) ALBO-OS and (b) Bio-Oss. Particles ofmaterial ALBO-OS (yellow
arrow) and Bio-Oss (green arrow) surrounded by fibroblasts and many multinuclear foreign body giant cells. A significantly larger number
of giant cells around the Bio-Oss particles were observed (HE stain, magnification 100x).
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Table 6: Presence of neoangiogenesis, mineralization, and connective tissue in defects 12 weeks after implantation of ALBO-OS and Bio-Oss.
Parameter Response Percentage of defects 𝑝 valueALBO-OS/Bio-OssALBO-OS Bio-Oss Without
Neoangiogenesis
No 55 57.1 —
1.0001–3 bv/HPM 35 28.6 —
4–7 bv/HPM 10 14.3 —
Mineralization
No 0 0 20
<0.001
<25% 0 28.6 60
25–50% 0 57.1 20
51–75% 30 14.3 0
76–100% 70 0 0
Connective tissue
No 75 0 0
<0.0010–25% 25 14.3 0
26–50% 0 28.6 30
51–100% 0 57.1 70
were significantly different in these groups (Table 6). Signifi-
cantly higher mineralization is observed in defects filled with
ALBO-OS, in comparison to Bio-Oss. The connective tissue
was not observed in even 75% defects filled with ALBO-OS,
while in the case of Bio-Oss connective tissue was present in
high percentage in the largest number of defects (57.1%). Post
hoc testing regarding mineralization and connective tissue
showed significant differences between Bio-Oss and ALBO-
OS (𝑝 < 0.001).
The newly formed bone at the site of ALBO-OS implan-
tation showed the regular structure of the bone beds (Fig-
ure 6(a)).The presence of mineralized osteoid was dominant.
Bone tissue showed lamellar structure. At the site of Bio-
Oss implantation, beds of new bone were filling the defect
in an irregular schedule (Figure 6(b)). The beds contained
approximately the same amount of unmineralized and min-
eralized osteoid. The particulates of unchanged material can
be observed in Figure 6(b). All this suggests that the process
of maturation of newly formed bone in the case of ALBO-OS
is in the final stage, unlike the case of Bio-Oss where the bone
is in an early phase of formation.
4. Conclusions
The synthesized bone scaffold based on CHA and PLGA
showed a very high porosity and nanotopology suitable for
cell adhesion and proliferation.
The results of the test of cutaneous irritation after appli-
cation of ALBO-OS on rabbits’ skin showed that ALBO-
OS is not irritant, while the results of the test of acute
systemic toxicity showed that ALBO-OS does not exhibit any
symptoms of toxicity in mice, according to the standard ISO
10993.
Biofunctionality tests performed six weeks after implan-
tation of ALBO-OS and Bio-Oss showed the presence of
particles of both materials, pronounced fibrovascular prolif-
eration with many blood vessels and new bone production
in an initial phase. Tests performed after nine weeks showed
certain advantages of ALBO-OS, expressed as lower number
of immune cells and higher degree of mineralization.
Tests performed after twelve weeks showed that the
immune response, expressed over the number of macro-
phages and giant cells, in the defects with ALBO-OS was
statistically lower than in defects with Bio-Oss. Significantly
higher degree of mineralization and lower degree of connec-
tive tissue in defects with ALBO-OS in comparison to those
with Bio-Oss indicate clearly that the formation of a new
bone is in its final stage for ALBO-OS, while for Bio-Oss it
is in an early stage. Lamellar structure of a new bone typical
for mature bone also confirmed that the osteointegration is
almost completed in defects filled with ALBO-OS.
All these indicate that ALBO-OS can be successfully
applied as a bone substitute in dental and maxillofacial
surgery.
Appendix
A. Scaffold Synthesis
The synthesis of the scaffold, called ALBO-OS, consisted
of three stages. The first one was the hydrothermal syn-
thesis of HA powder from an approximately stoichiometric
mixture of (NH
4
)
2
HPO
4
and Ca(OH)
2
[15]. Briefly, 500mL
of 2.32 cmol aqueous solution of (NH
4
)
2
HPO
4
was poured
into 500mL of 3.02 cmol aqueous solution of Ca(OH)
2
,
under vigorous stirring. The mixture pH was adjusted to
7.4, and then it was autoclaved at 150∘C under a pressure
of 5 ⋅ 105 Pa for 8 h. After the hydrothermal treatment, the
precipitate was decanted, dried at 80∘C for 48 h, washed with
deionized water, and centrifuged. In the next step, 5 g of
hydrothermally synthesized HA and 1.5 g of poly(ethylene
vinyl acetate)/poly(ethylene vinyl versatate) (PEVA/PEVV)
were mixed and further processed in the autoclave at 120∘C
for 2 h.
The obtained HA powder was ultimately used for the
production of HA granules. First, it was mixed with water
to form ceramic slurry. To enhance the wettability of the
slurry and its rheological properties, 2% of PVA was added.
Polyurethane (PU) foamswith required pore size distribution
were then dipped into the slurry and gently squeezed several
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Figure 6: A typical appearance of newly formed bone 12 weeks after implantation: (a) ALBO-OS: regular structure of bone beds in new bone;
dominant presence of mineralized osteoid; lamellar structure of bone tissue; (b) Bio-Oss: newly formed bone beds which are of irregular
structure; amounts of mineralized and unmineralized osteoid which are approximately the same; material particulates which are visible
(Masson’s trichrome stain, magnification 40x).
times to allow the slurry to penetrate the foams and the excess
slurry to be squeezed out. Compressed air through an air
gun was used to avoid the blockage of pores. The ceramic
slurry coated PU foams were left to dry at room temperature,
then heated in an oven at 600∘C to burn away the foam,
and finally sintered at 1200∘C for 4 h. The obtained porous
HA compact was further disintegrated into granules of sizes
300 𝜇m–1mm.
The final step in ALBO-OS synthesis was the deposition
of a thin film of PLGAonto the surface ofHA granules. PLGA
pellets (Durect Corporation, 50 : 50,𝑀 = 45000–70000) were
dissolved in chloroform to obtain a 1% w/w solution, which
was then poured over the HA granules. After the solvent
evaporation, thin PLGA film was formed on the granule
surfaces.
B. Micro Computed Tomography
Scaffold specimen was scanned using micro computed
tomography (CT) (SkyScan, Bruker 1172, Kontich, Belgium)
with a source voltage of 100 kV, a current of 100 𝜇A, exposure
time of 1000ms, and copper aluminium filter. The specimen
was attached to a stage that rotated 180∘ with images acquired
every 0.4∘. The slice thickness was 5𝜇m isotropic resolution
and 2,048 × 2,048 pixels per slice. Cross-sectional slices
were reconstructed using the NRecon v.1.6.9.8 software with
beam hardening correction of 10%, ring artifact correction of
9%, postalignment of −2.5, and smoothing of 2. For poros-
ity assessment, CTAn 1.14.4.1 software (SkyScan, Bruker)
was used for all analyses. CTAn 1.14.4.1 software (SkyScan,
Bruker) with threshold set to 66–256 values was employed
to distinguish scaffold and air allowing determination of
following structural morphometric parameters: total and
open porosity (%), average pore size and pore size distribu-
tion (𝜇m), structure model index, and connectivity density
(1/mm3).
C. Surgical Procedure
Dissociative anesthesia was conducted in all surgical pro-
cedures. The animals were premedicated by intramuscular
administration of Xylazine (2% Xylazine, 5mg/kg body
weight, Cp Pharma, Bergdorf, Germany), followed by intra-
muscular administration of Ketamine (Ketamine 500mg/
mL, 35mg/kg body weight, Laboratorio Sanderson SA,
Santiago, Chile) and Acepromazine (Acepromazine 50mL,
0.75mg/kg body weight, Boehringer Ingelheim Vetmedica,
Inc., St. Joseph, MO 64506, USA).
The surgical procedure was performed under aseptic
conditions in a manner that ensures minimal trauma. The
scalp of rabbits was shaved and disinfected with iodine
solution, and then an incision in the middle skull base was
performed. The central incision on the rabbit head stretched
from the parietal (os parietale, sutura coronalis) to the
frontal bone (os frontale, incisura supraorbitalis caudalis).
Musculus frontalis and musculus frontoscutularis were cut
to the parietal and frontal bones. Skin and periosteum were
carefully cut and withdrawn to reveal parietal bones. On both
sides of calvaria, two full thickness critical sized (6.0mm in
diameter) defects weremade using a trepan borer (ACDental
Implant System, trepan borer 6.0mm, total length 32mm,
blade length 15.8mm, inner diameter 6mm, outer diameter
6.95mm, titanium alloy), with a continuous flushing with
saline solution (Natrii Chloridi Infundibile, solution for
infusion, Zdravlje AD Leskovac, Serbia).
The bone tissue was removed with a sharp excavator.
Randomization of the tested materials was carried out by
the materials distribution using rotational technique (in a
clockwise direction, in accordance with the modified Latin
square design) to ensure a balanced distribution of the
materials between the front and rear regions of the calvaria
bone. The skin is then returned to its place to cover the
experimental area and was stitched up with sutures (4-0
Sofsilk, Syneture, England) applying horizontal mattress
sutures.
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Table 7: Statistical 𝑝 values for the presence of various immune cells in defects filled with ALBO-OS or Bio-Oss and empty critical defects.
𝑝 values
Bio-Oss ALBO-OS Overall
Empty defects
Macrophages 0.016 <0.001 <0.001
Giant cells 0.146 <0.001 <0.001
Lymphocytes 0.762 0.108 0.105
Plasma cells 0.487 0.108 0.110
Basophils 1.000 0.231 0.253
Table 8: Statistical 𝑝 values for the presence of mineralization and connective tissue in defects filled with ALBO-OS or Bio-Oss and empty
critical defects.
𝑝 values
Bio-Oss ALBO-OS Overall
Empty defects Mineralization 0.012 <0.001 <0.001
Connective tissue 0.370 <0.001 <0.001
Postoperatively, the animals were injected subcuta-
neously with analgesics (Moradol, Galenika, Serbia) at a dose
of 0.1 to 2.0mg/kg of bodyweight every 8 hours for three days.
Antibiotic (Chloramphenicol, Galenika, Serbia) at a dose of
60mg/kg of body weight was administered once daily for five
days. The animals were placed in individual cages until the
end of the experiment. All animals recovered well after the
surgical procedures without any signs of infection, and skin
wounds healed per primam intentionem.
After an assessment period of 12 weeks, the animals were
sacrificed with intravenous injection of 10mL Pentobarbital
(Sigma-Aldrich, Germany). After that, the parietal bones
were cut out and immersed in 10% formalin.
D. Statistical Analysis
Based on the results of statistical analysis, it was showed
that there are statistically significant differences between
groups of macrophages and giant cell (Table 7). When it
comes to macrophages, subsequent testing between groups
determined that there is a statistically significant difference
between empty defects and Bio-Oss (𝑝 = 0.016) and empty
defects and ALBO-OS (𝑝 < 0.001). The same analysis
shows that when it comes to giant cell, there is no significant
difference between empty defects and Bio-Oss (𝑝 = 0.146),
but there is a significant difference between empty defects and
ALBO-OS (𝑝 < 0.001).
Table 8 clearly shows that the difference between groups
mineralization and connective tissue is significant. By subse-
quent testing between groups of mineralization, it was estab-
lished that the difference is significant between the empty
defects and Bio-Oss (𝑝 = 0.012) and between the empty
defects and ALBO-OS (𝑝 < 0.001). For connective tissue
(fibroplasia), the differences were not significant between the
empty defects and Bio-Oss (𝑝 = 0.370), while the differences
were significant between the empty defects and ALBO-OS
(𝑝 < 0.001).
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